From WBA’s post this morning ‘Currently, Brickell Biotech’s Ecclock (sofpironium bromide) is the only anticholinergic pipeline agent in Phase III development. Despite having superior efficacy to Qbrexza, Ecclock gel does not offer a better delivery method.’
I reckon BOT thinks Permetrex is the delivery method that will set it apart from the competition.
Ann: Dermatology Asset Acquired to Accelerate Path to Revenue, page-40
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.030(8.70%) |
Mkt cap ! $570.1M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 33.8¢ | 31.0¢ | $1.179M | 3.676M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 461505 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 53870 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |